

**Suspend the Rules and Pass the Bill, H. R. 2241, With an
Amendment**

**(The amendment strikes all after the enacting clause and inserts a
new text)**

114TH CONGRESS
1ST SESSION

H. R. 2241

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

IN THE HOUSE OF REPRESENTATIVES

MAY 5, 2015

Mr. SIRES (for himself and Mr. DIAZ-BALART) introduced the following bill;
which was referred to the Committee on Foreign Affairs

A BILL

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Global Health Innova-
3 tion Act of 2015”.

4 **SEC. 2. ANNUAL REPORT.**

5 (a) IN GENERAL.—Not later than 180 days after the
6 date of the enactment of this Act, and annually thereafter
7 for a period of 4 years, the Administrator of the United
8 States Agency for International Development shall submit
9 to Congress a report on the development and use of global
10 health innovations in the programs, projects, and activities
11 of the Agency.

12 (b) MATTERS TO BE INCLUDED.—The report re-
13 quired by subsection (a) shall include the following:

14 (1) A description of—

15 (A) the extent to which global health inno-
16 vations described in subsection (a) include
17 drugs, diagnostics, devices, vaccines, electronic
18 and mobile health technologies, and related be-
19 havior change and service delivery innovations;

20 (B) how innovation has advanced the
21 Agency’s commitments to achieving an HIV/
22 AIDS-free generation, ending preventable child
23 and maternal deaths, and protecting commu-
24 nities from infectious diseases, as well as
25 furthered by the Global Health Strategic
26 Framework;

1 (C) how goals are set for health product
2 development in relation to the Agency's health-
3 related goals and how progress and impact are
4 measured towards those goals;

5 (D) how the Agency's investments in inno-
6 vation relate to its stated goals; and

7 (E) progress made towards health product
8 development goals.

9 (2) How the Agency both, independently and
10 with partners, donors, and public-private partner-
11 ships, is—

12 (A) leveraging United States investments
13 to achieve greater impact in health innovation;

14 (B) engaging in activities to develop, ad-
15 vance, and introduce affordable, available, and
16 appropriate global health products; and

17 (C) scaling up appropriate health inno-
18 vations in the development pipeline.

19 (3) A description of collaboration and coordina-
20 tion with other Federal departments and agencies,
21 including the Centers for Disease Control and Pre-
22 vention, in support of global health product develop-
23 ment, including a description of how the Agency is
24 working to ensure critical gaps in product develop-
25 ment for global health are being filled.

1 (4) A description of how the Agency is coordi-
2 nating and aligning global health innovation activi-
3 ties between the Global Development Lab, the Cen-
4 ter for Accelerating Innovation and Impact, and the
5 Bureau for Global Health.